The panel of markers being acquired by Miraculins has shown evidence of its ability to diagnose the disease in its earliest stages.
According to Miraculins, a reliable test for pre-eclampsia has the potential to be used as a general screen for all pregnant women, representing a market of 6.4 million women annually in the US alone.
Further details of the agreement will be made available upon execution of the full licensing agreement, expected to occur within 45 days
Christopher Moreau, president and CEO of Miraculins, said: “This is the first transaction for the company after recently announcing our new focus on technology that has completed early research and discovery work.”